Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva:feasible for rifampicin, not for isoniazid
- Authors
- Publication date
- 1 October 2020
- Publisher
- 'European Respiratory Society (ERS)'
- Doi
Abstract
Abstract is not available.Similar works
Available Versions
Last time updated on 01/06/2022
Last time updated on 29/05/2021
Last time updated on 22/04/2023
Last time updated on 03/06/2022
Last time updated on 02/06/2022
Last time updated on 22/04/2023